ClinicalTrials.gg
RecruitingNCT06347874Updated Feb 17, 2026

Cryo Rib Fracture Study

A Phase 4 interventional study of Cryoablation and ESP Catheter in Rib Fractures, sponsored by University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by University of Minnesota · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Rib Fractures with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Rib Fractures · United States.

Planned enrollment
16th of 41
48 · median 36
Started
2025
with 4 others
Phase 4
17 of 48
3 open now
Registered
41st of 48
by date

Among the 48 studies in Rib Fractures with a site in United States, this one is the 16th largest by planned enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2025, is one of 17 in phase 4, and was the 41st registered.

Rib Fractures

126 studies on the registry are indexed under Rib Fractures; 28 are open to participants now.

Browse Rib Fractures studies →

Open to participants now

9 of the 48 studies in Rib Fractures with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Rib Fractures studies recruiting now, 9 (64%) set no upper age limit and 1 (7%) stops at 75 or younger; none take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Rib Fractures with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if patients with rib fractures who undergo cryoablation of the intercostal nerves have improved pain control 7 days from procedure when compared to those who have a ESP catheter.

03

Conditions studied

  • Rib Fractures

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are over 18 who have more than one ribs fractured.

Exclusion criteria

Exclusion Criteria:

  • Patients who have an exclusion to regional anesthesia.
  • Patients who are pregnant via self-report or pregnancy test if they take one.
  • Non-English speakers
  • Patients who have cold urticaria
  • Patients with bilateral fractures
  • Patients currently intubated
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Cryoablation

    Participants with rib fracture randomized to Cryoablation.

    Drug: Cryoablation

  • Active comparator
    ESP catheter

    Participants with rib fracture randomized to ESP Catheter.

    Drug: ESP Catheter

Interventions

  • DrugCryoablation

    an injection of 1ml of 1% lidocaine per rib and ultrasound guided cryoablation of the intercostal nerves

  • DrugESP Catheter

    an ultrasound guided erector spinae plane catheter with initial bolus of 30 mL of 0.25% bupivacaine followed by infusion of 0.2% ropivacaine at 10 mL per hour via programmed intermittent bolus.

06

What researchers measure

Primary outcomes

  1. Maximum pain score on POD (Post Operative Day) 7

    Maximum pain score on POD (Post Operative Day) 7

    Time frame: 7 days post procedure

  2. Opioid Use

    Opioid Use measured in MMEs

    Time frame: 30 days post procedure

  3. Functional Pain Scores

    Functional Pain Scores on POD 0,1,2,3,4,5,6,7,and 30

    Time frame: 30 days post procedure

  4. Number of Patients using opioids at POD 30

    , Number of Patients using opioids at POD 30

    Time frame: 30 days post procedure

  5. Length of hospital stay

    Length of hospital stay measured in days:hours:minutes

    Time frame: 30 days post procedure

  6. Number of patients returned home by POD 30

    Number of patients returned home by POD 30

    Time frame: 30 days post procedure

  7. time to first ambulation

    time to first ambulation measured in days:hours:minutes

    Time frame: 30 days post procedure

  8. number of patients admitted to ICU

    number of patients admitted to ICU

    Time frame: 30 days post procedure

  9. number of patients that required mechanical ventilation

    number of patients that required mechanical ventilation

    Time frame: 30 days post procedure

  10. Pulmonary Function Testing.

    Pulmonary Function Tests include spirometry. For patients with pulmonary function testing, the test results between the two groups.

    Time frame: 30 days post procedure

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Feb 2027, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2024
First posted
Apr 4, 2024
StartActual
Jan 10, 2025
Primary completionEst.
Feb 13, 2027
CompletionEst.
Mar 13, 2027
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06347874
Responsible party
Sponsor
First posted
Apr 4, 2024
Start date
Jan 10, 2025
Primary completion
Feb 13, 2027 (estimated)
Completion
Mar 13, 2027 (estimated)
Last update
Feb 17, 2026

Study contacts

Candace Nelson
Contact
nelso377@umn.edu
Neil Hanson
principal investigator · University of Minnesota

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion